https://www.newswire.ca/news-releases/aeterna-zentaris-data-safety-monitoring-board-recommends-continuation-of-phase-3-study-of-zoptarelin-doxorubicin-in-advanced-endometrial-cancer-517493411.html
Aeterna Zentaris: Data Safety Monitoring Board Recommends Continuation of Phase 3 Study of...
/CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the independent Data Safety Monitoring Board ("DSMB") for...
data safety monitoring board